Sumitani Ryohei, Harada Takeshi, Nakamura Masafumi, Mizuguchi Makiko, Oura Masahiro, Sogabe Kimiko, Maruhashi Tomoko, Takahashi Mamiko, Fujii Shiro, Nakamura Shingen, Miki Hirokazu, Kagawa Kumiko, Yada Mio, Matsudate Yoshihiro, Uehara Hisanori, Abe Masahiro
Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences.
Department of Hematology, Tokushima Prefectural Central Hospital.
Rinsho Ketsueki. 2022;63(6):536-543. doi: 10.11406/rinketsu.63.536.
The standard therapies for primary cutaneous anaplastic large cell lymphoma (pcALCL) in an advanced stage remain undefined. A 71-year-old man presented with multiple erythema and nodules. He was diagnosed with lymphomatoid papulosis (LyP) through a skin biopsy from the left postauricular area. All skin lesions achieved complete response by electron beam irradiation. However, nodular lesions appeared in both inner canthi 5 months later. Histopathological evaluation of the lesional biopsy revealed dominant infiltration of CD30-positive large cells. Positron emission tomography/computed tomography revealed fluorodeoxyglucose-positive cervical and inguinal lymph node swelling and right tonsillitis, followed by the diagnosis of pcALCL and TNM classification T3bN3M0. Since the patient had severe chronic obstructive pulmonary disease and recurrent pneumonia, he received low-dose methotrexate (MTX) (15 mg/week) therapy. Low-dose MTX effectively debulked the lymphadenopathies over time without particular adverse effects. Although the standard therapies for pcALCL are not established, low-dose MTX was effective and considered safe for patients with frailty and compromised respiratory function. Further study is warranted on the pathophysiology of pcALCL after the development of LyP and mechanisms of action of low-dose MTX against LyP and pcALCL.
